BTK and mantle cell lymphoma: The introduction of BTK inhibitors as part of the treatment regimen in chronic lymphatic leukemia (CLL), lymphoplasmacytic lymphoma (LPL) and mantle cell lymphoma (MCL) has been very successful [2].